Venus Remedies (BOM:526953) ROCE %: 35.62% (As of Mar. 2026)

What is Venus Remedies ROCE %?

Venus Remedies BOM:526953 +4.99% 52 ROCE % is 35.62% as of Mar. 2026. GuruFocus rates BOM:526953 with a GF Score™ of 52/100 and a GF Value™ of ₹467.09 (Significantly Overvalued). The stock has 5 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Venus Remedies's annualized ROCE % for the quarter that ended in Mar. 2026 was 35.62%.

Venus Remedies (BOM:526953) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Venus Remedies ROCE % Related Terms

Venus Remedies ROCE % Historical Data

* Premium members only.

The historical data trend for Venus Remedies's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Venus Remedies ROCE % Chart

Venus Remedies Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

ROCE %

Get a 7-Day Free Trial

7.74

7.57

8.39

12.76

21.11

Venus Remedies Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
ROCE %	Get a 7-Day Free Trial															21.43	8.71	16.96	21.43	35.62

52GF Score

Venus Remedies Ltd BOM:526953

ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Venus Remedies ROCE % Calculation

Venus Remedies's annualized ROCE % for the fiscal year that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Mar. 2026 )		(A: Mar. 2025 )		(A: Mar. 2026 )
	=	1342	/	( ( (7157.215 - 1362.886)	+	(8537 - 1617.6) )	/ 2 )
	=	1342	/	( (5794.329	+	6919.4)	/ 2 )
	=	1342	/	6356.8645
	=	21.11 %

Venus Remedies's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Mar. 2026 )		(Q: Dec. 2025 )		(Q: Mar. 2026 )
	=	2464.8	/	( ( (0 - 0)	+	(8537 - 1617.6) )	/ 1 )
	=	2464.8	/	( ( 0	+	6919.4 )	/ 1 )
	=	2464.8	/	6919.4
	=	35.62 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

Frequently Asked Questions Learn more about ROCE % →

What does a ROCE % of 35.62% mean?

Venus Remedies (BOM:526953) has a ROCE % of 35.62% as of Mar. 2026.

Is Venus Remedies' ROCE % too high?

Venus Remedies' current ROCE % is 35.62%. The Drug Manufacturers industry median ROCE % is 7.01. Venus Remedies' value of 35.62% is 408.1% above this industry median. Overall, Venus Remedies has a GF Score™ of 52/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.

How does Venus Remedies' ROCE % compare to ZTS?

Venus Remedies' ROCE % of 35.62% can be compared against companies in the Drug Manufacturers industry. The industry median ROCE % is 7.01. Venus Remedies' value of 35.62% is 408.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good ROCE % for a Drug Manufacturers company?

The median ROCE % among Drug Manufacturers companies is 7.01, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a ROCE % significantly above this median, while those in the bottom quartile fall well below. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Venus Remedies's current ROCE % of 35.62% is 408.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high ROCE % mean?

A high ROCE % can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median ROCE % is 7.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Venus Remedies's current ROCE % is 35.62%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Venus Remedies stock overvalued right now?

Based on GuruFocus' analysis, Venus Remedies (BOM:526953) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹467.09, compared to a current price of ₹1,945.90 — trading 316.6% above its estimated fair value. The current ROCE % is 35.62% and 408.1% above the Drug Manufacturers industry median of 7.01. Venus Remedies' overall GF Score™ is 52/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is ROCE % calculated?

ROCE % is calculated from a company's financial statements. For Venus Remedies (BOM:526953), the current ROCE % is 35.62% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Venus Remedies (BOM:526953) Overvalued in 2026?

Based on GuruFocus' analysis, Venus Remedies stock appears to be overvalued. The current stock price of ₹1,945.90 is trading 316.6% above its estimated GF Value™ of ₹467.09. GuruFocus considers Venus Remedies to be Significantly Overvalued.

Key valuation signals for BOM:526953:

ROCE %: 35.62%
GF Value™: ₹467.09 vs. price of ₹1,945.90 (316.6% above fair value)
GF Score™: 52/100 with 5 warning signs
Industry Position: 408.1% above the Drug Manufacturers median

No single metric tells the full story. See the BOM:526953 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Venus Remedies Business Description

Industry Healthcare Drug Manufacturers

Comparable Companies BOM:543329 BOM:524669 NSE:SAKAR BOM:590006 BOM:532612 NSE:BETA BOM:524470 BOM:507789 BOM:539730 BOM:532305 XTER:MRK TSE:4502 XSWX:GALD SHSE:600276 NSE:SUNPHARMA XTAE:TEVA LSE:HLN XSWX:SDZ ZTS HKSE:03692

Other Exchanges VENUSREM:India

Address Plot 51-52, Industrial Area, Phase 1, Panchkula, HR, IND, 134113

Website https://www.venusremedies.com

Venus Remedies Ltd is an Indian drug manufacturer. It is engaged in manufacturing and trading pharmaceutical products. The company produces biologically active food supplements which include food supplements are natural complexes containing minerals, vitamins, dietary fibers, extracts of medicinal herbs, amino acids and others.

52GF Score

Get the complete analysis for BOM:526953

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹1,945.90

Price

₹467.09

GF Value

View BOM:526953 Analysis

See ROCE % data for all stocks →